

# Curriculum Vitae Richard Barry Wilder, M.D.

## Personal Data

Name: Richard Barry Wilder, M.D.  
Citizenship and Visa Status: United States of America  
Office Address: Cancer Center of Irvine  
16100 Sand Canyon Avenue, Suite 130  
Irvine, CA 92618-3722  
Phone: (949) 417-1100  
Home Address: 11 Sarteano Dr.  
Newport Coast, CA 92657-1627  
Phone: (949) 715-1926

## Education

### Degree-Granting Education

Stanford University, Stanford, CA, B.S, 1981-1984, Biology & Chemical Engineering  
Stanford University, Stanford, CA, M.S., 1983-1984, Biology  
University of Maryland, Baltimore, M.D., 1985-1988, Medicine  
Johns Hopkins University Carey Business School, MBA, 2006-2007, Finance

### Postgraduate Training

Internal Medicine Internship, Greater Baltimore Medical Center, Baltimore, MD,  
Thaddeus Prout, M.D., 1988-1989  
Radiation Oncology Residency, University of Arizona, Tucson, AZ,  
J. Robert Cassady, M.D., 1989-1993  
Radioimmunotherapy Fellowship, Stanford University Medical Center, Stanford, CA,  
Susan J. Knox, Ph.D., M.D., 1991-1992

## Board Certification

American Board of Radiology Certificate in Radiation Oncology, 1993

### Licensure(s)

California, G70907, 1999-present (active)  
Texas, K9454, 2000-present (active)  
Arizona, 18935, 1989 -1990 (inactive)

## Experience / Service

### Academic Appointments

Assistant Professor, Department of Radiation Oncology, University of California, Davis and University of California, San Francisco, CA, 1993-1999

Assistant Professor, Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 1999-2002

Associate Professor, Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2002

### Institutional Committee Activities

Member, Radiation Oncology Resident Search Committee, University of Arizona, 1989-1993

Member, Radiation Oncology Resident Selection Committee, University of California, San Francisco, 1993-1994

Member, Radiation Oncology Faculty Search Committee, University of California, Davis, 1993-1994

Member, Radiation Use Committee, University of California, Davis, 1994-1997

Member, Radiation Therapist Selection Committee, University of California, Davis, 1995

Member, Radiation Oncology Records Committee, University of California, Davis, 1995

Member, Radiation Oncology Chairman Search Committee, University of California, Davis, 1995

Interviewer, Medical School Admissions Committee, University of California, Davis, 1994-1999

Member, Cancer Center Scientific Subcommittee, University of California, Davis, 1997-1999

Member, Pharmacy & Therapeutics Committee, University of Texas M. D. Anderson Cancer Center, 2001-2002

### Other Appointments / Responsibilities

Establishment of an article file for radiation oncology residents at Stanford University, University of California, San Francisco, University of California, Davis, and University of Texas M. D. Anderson Cancer Center, 1993-1999

Initiate radiation oncology resident teaching conference and schedule weekly topics and speakers, University of California, Davis, 1996-1997

Co-Director, Stereotactic Radiosurgery Program, University of California, Davis, 1994-1999

Oral Board Guest Examiner (1 of 8 lymphoma examiners; half of them examine each year), American Board of Radiology, 2002-present

Radiation Oncology Written Exam Lymphoma Item Writing Task Force, American Board of Radiology, 2005-present

Expert Panel on Hodgkin's Disease for the Committee on Appropriateness Criteria of the American College of Radiology, 2008

### Military or Other Governmental Service

Civilian Contractor, Radiation Therapy Service, Walter Reed Army Medical Center, Washington, DC, 2002-2007

## Honors and Awards

Departmental Honors in Biology (graduation from Stanford University with honors), 1984

*National Institutes of Health Summer Research Fellowship, 1984*

American Society for Therapeutic Radiology and Oncology (ASTRO) Travel Award to Present at the 32nd Annual Meeting, 1990

ASTRO Research Fellowship, 1991-1992

Stipend from the Robert D. Plageman Memorial Fund (Stanford Medical School Dean's postdoctoral fellowship), 1991-1992

Employee Recognition Program Award for Patient Care, U. C. Davis Medical Center, 1993

U. C. Davis Academic Senate Research Travel Award to Present at ASTRO's 38th Annual Meeting, 1996

ASTRO Travel Award to spend a week in the radiation oncology department at the Royal Marsden Hospital in London, England as part of the ASTRO-ESTRO Exchange Program and attend the 17th Annual ESTRO Meeting in Edinburgh, Scotland, 1998

Teacher of the Year Award, Radiation Oncology Residency Program, National Capital Consortium/National Cancer Institute, 2003-2004

## Research

### Grants and Contracts

Co-investigator, Development of a molecular basis for targeted therapy, DOE DE-FG03-84ER60233, PI - Sally J. DeNardo, M.D., 1992-1996, \$2,425,000 (\$606,250/year)

Co-investigator, Studies to improve cancer treatment with antibodies, CA 47829, Gerald L. DeNardo, M.D., 1994-1999, \$5,100,000 (\$1,020,000/year)

#### Funded Protocols

Co-principal Investigator, MR/CT image correlation for radiosurgery treatment planning, PI - Robin L. Stern, Ph.D., 1996-1997, \$3,000 (\$3,000/year)

Co-principal Investigator, Dose comparison of rotational multi-arc vs. static mini MLC-based radiosurgery, PI – Dale Kubo, Ph.D., 1996-1997, \$1,500 (\$1,500/year)

Co-investigator, A phase I dose escalating study of the safety of gadolinium texaphyrin as a radiosensitizer in patients with glioblastoma multiforme, NCI R03 grant T97-0108, PI - Judith Ford, M.D., Ph.D. (U.C.L.A.), 1998-1999, \$10,715 (\$10,715/year)

Co-principal Investigator, Phase I/II radioimmunotherapy of non-Hodgkin's lymphoma with radiolabeled humanized Immu-LL2: Treatment with <sup>90</sup>Y-hLL2 IgG, Protocol #ID01-578, PI – Luis Fayad, M.D., 2001

Principal Investigator, Breast dose reduction by treating women in a custom prone immobilization device, Protocol #ID01-667, 2002, \$5,180 (\$5,180/year)

Co-investigator at Cancer Center of Irvine, A multi-site, prospective, non-randomized study utilizing the Contura™ multi-lumen balloon (MLB) breast brachytherapy applicator to deliver accelerated partial breast irradiation: analysis of dosimetric success, local tumor control, cosmetic outcome, acute and chronic toxicity, and clinical scenarios for optimal use, PI – Kenneth Tokita, M.D., 2008-2009, (\$15,000/year)

Co-investigator, Transperineal injection of cross-linked hyaluronan gel into anterior perirectal fat to reduce rectal toxicity from high dose rate brachytherapy and/or intensity-modulated radiation therapy for prostate cancer, PI – Kenneth Tokita, M.D., 2008-2009, \$165,000 (\$82,500/year)

Principal Investigator, Registry study of the Contura™ multi-lumen balloon (MLB) applicator for accelerated partial breast irradiation in intermediate-risk, pathological stage 0, I, or II (up to 3.0 cm) breast cancer patients, 2008-2009, \$135,000 (\$67,500/year)

#### Grant Reviewer/Service on NIH/Other Study Sections

Reviewer of British Cancer Research Campaign Project Grant Applications, 1999-2002

## Publications

### A. Articles in Peer-Reviewed Journals

(\*: Corresponding author, with a medical school student or radiation oncology resident as the first author)

1. **Wilder RB**, Harari PM, Graham AR, Shimm DS, Cassady JR. Merkel cell carcinoma: Improved locoregional control with postoperative radiation therapy. *Cancer* 68(5):1004-8, 1991.
2. Shimm DS, **Wilder RB**. Radiation therapy for squamous cell carcinoma of the skin. *American Journal of Clinical Oncology* 14(5):383-6, 1991.
3. **Wilder RB**, Shimm DS, Kittelson JM, Rogoff EE, Cassady JR. Recurrent basal cell carcinoma treated with radiation therapy. *Archives of Dermatology* 127(11):1668-72, 1991.
4. **Wilder RB**, Kittelson JM, Shimm DS. Basal cell carcinoma treated with radiation therapy. *Cancer* 68(10):2134-7, 1991.
5. **Wilder RB**, Buatti JB, Kittelson JM, Shimm DS, Harari PM, Rogoff EE, Cassady JR. Pterygium treated with excision and postoperative beta irradiation. *International Journal of Radiation Oncology, Biology, Physics* 23(3):533-7, 1992.
6. **Wilder RB**, Langmuir VK, Mendonca HL, Goris ML, Knox SJ. Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. *Cancer Research* 53(13):3022-7, 1993.
7. **Wilder RB**, McGann JK, Sutherland WR, Waller EK, Minchinton AI, Goris ML, Knox SJ. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. *International Journal of Radiation Oncology, Biology, Physics* 28(1):119-26, 1994.
8. **Wilder RB**. Treatment of arteriovenous malformations with stereotactic radiosurgery: A review. *Radiation Oncology Investigations* 2:57-65, 1994.
9. Shui C, Khan WB, Leigh BR, Turner AM, **Wilder RB**, Knox SJ. Effects of stem cell factor on the growth and radiation survival of tumor cells. *Cancer Research* 55(15):3431-7, 1995.

10. **Wilder RB**, Fowler JF, DeNardo GL, Shen S, Wessels BW, DeNardo SJ. Use of the linear-quadratic model to compare doses delivered to the bone marrow by  $^{131}\text{I}$ -Lym-1 radioimmunotherapy. *Antibody, Immunoconjugates, and Radiopharmaceuticals* 8(4):227-39, 1995.
11. **Wilder RB**, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. *Journal of Clinical Oncology* 14(4):1383-1400, 1996.
12. **Wilder RB**, DeNardo GL, Shen S, Fowler JF, Wessels BW, DeNardo SJ. Application of the linear-quadratic model to myelotoxicity associated with radioimmunotherapy. *European Journal of Nuclear Medicine* 23(8): 953-7, 1996.
13. **Wilder RB**, Fone PD, Rademacher DE, Jones CD, Roach M 3rd, Earle JD, White RD. Localization of the prostatic apex for radiotherapy treatment planning using urethroscopy. *International Journal of Radiation Oncology, Biology, Physics* 38(4):737-41, 1997.
14. Lau D, Ryu J, Gandara D, Morgan R, Doroshov J, **Wilder R**, Leigh B. Twice-weekly paclitaxel and radiation for stage III non-small cell lung cancer. *Seminars in Oncology* 24(Suppl 12):S12-106-S12-109, 1997.
15. Kubo HD, Pappas CT, **Wilder RB**. A comparison of arc-based and static mini-multileaf collimator-based radiosurgery treatment plans. *Radiotherapy and Oncology* 45(1):89-93, 1997.
16. Seung SK, Kroll S, **Wilder RB**, Posner MD, Roach M 3rd. Candidates for prostate radioactive seed implantation treated by external beam radiotherapy. *Cancer Journal From Scientific American* 4(3):168-74, 1998.
17. Shen S., DeNardo GL, Jones TD, **Wilder RB**, O'Donnell RT, DeNardo SJ. A preliminary cell-kinetics model of thrombocytopenia after radioimmunotherapy. *Journal of Nuclear Medicine* 39(7):1223-9, 1998.
18. Lau D, Ryu J, Gandara D, Morgan R, Doroshov J, **Wilder R**, Leigh B. Concurrent twice-weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. *Seminars in Radiation Oncology* 9 (2 Suppl1): 117-20, 1999.
19. Kubo HD, **Wilder RB**, Pappas CTE. Impact of collimator leaf width on stereotactic radiosurgery and 3D conformal radiotherapy treatment plans. *International Journal of Radiation Oncology, Biology, Physics* 44(4):937-45, 1999.

20. Michalski JM, Purdy JA, Winter K, Roach III M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, **Wilder RB**, Hanks GE, Cox JD. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. *International Journal of Radiation Oncology, Biology, Physics* 46(2):391-402, 2000.
21. Chou RC, **Wilder RB**, Ji M, Ryu JK, Leigh BR, Earle JD, Doggett RL, Kubo HD, Roach M III, DeVere White R. Acute toxicity of three dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy. *International Journal of Radiation Oncology, Biology, Physics* 47(1):115-9, 2000.
22. **Wilder RB**, Hsiang JY, Ming J, Earle JD, DeVere White R. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy. *American Journal of Clinical Oncology* 23(2):176-80, 2000.
23. **Wilder RB**, Chou RH, Ryu JK, Stern RL, Wong MS, Ji M, Roach M III, DeVere White R. Potency preservation following three dimensional conformal radiotherapy for prostate cancer: Preliminary results. *American Journal of Clinical Oncology* 23(4):330-3, 2000.
24. Schlembach PJ, \***Wilder RB**, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD. Impact of involved field radiotherapy after CHOP-based chemotherapy on stage III-IV, intermediate grade and large-cell immunoblastic lymphomas. *International Journal of Radiation Oncology, Biology, Physics* 48(4):1107-10, 2000.
25. Kubo HD, **Wilder RB**, Pappas CT, Earle JD, Stern RL. Two-staged radiosurgical treatment of large arteriovenous malformations. *Journal of Radiosurgery* 3(3):105-11, 2000.
26. **Wilder RB**, Tucker SL, Ha CS, Rodriguez MA, Hess MA, Cabanillas FF, Cox JD. Dose-response analysis for radiotherapy delivered to patients with intermediate-grade and large-cell immunoblastic lymphomas that have completely responded to CHOP-based induction chemotherapy. *International Journal of Radiation Oncology, Biology, Physics* 49(1):17-22, 2001.
27. Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, **Wilder R**, Ryu J, Doroshow J. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small cell lung cancer: A California Cancer Consortium phase II trial. *Journal of Clinical Oncology* 19(2):442-7, 2001.
28. Ha CS, Shadle KM, Medeiros LJ, **Wilder RB**, Hess MA, Cabanillas F, Cox JD. Localized non-Hodgkin's lymphoma involving the thyroid gland. *Cancer* 91(4):629-35, 2001.

29. **Wilder RB**, Rodriguez MA, Tucker SL, Ha CS, Hess MA, Cabanillas FF, Cox JD. Radiation therapy after a partial response to CHOP chemotherapy for aggressive lymphomas. *International Journal of Radiation Oncology, Biology, Physics* 50(3):743-9, 2001.
30. **Wilder RB**, Rodriguez MA, Ha CS, Pro B, Hess MA, Cabanillas FF, Cox JD. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. *Cancer* 91(12):2440-6, 2001.
31. Pelloski CE, \***Wilder RB**, Ha CS, Hess MA, Cabanillas FF, Cox JD. Clinical stage IEA-IIEA orbital lymphomas: Outcomes in the era of modern staging and treatment. *Radiotherapy and Oncology* 59:145-51, 2001.
32. Chronowski GM, Ha CS, **Wilder RB**, Cabanillas F, Manning J, Cox JD. Treatment of unicentric and multicentric Castleman's disease and the role of radiotherapy. *Cancer* 92(3):670-6, 2001.
33. Ha CS, Tucker SL, Blanco AI, **Wilder RB**, McLaughlin P, Cabanillas F, Cox JD. Hematological recovery after central lymphatic irradiation for patients with stage I-III follicular lymphoma. *Cancer* 92(5):1074-9, 2001.
34. Chou RH, **Wilder RB**, Wong MS, Forster KM. Recent advances in radiotherapy for head and neck cancers. *Ear, Nose, & Throat Journal* 80(10):704-7, 711-4, 716 passim, 2001.
35. **Wilder RB**, Jones D, Tucker SL, Fuller, LM, Ha CS, McLaughlin P, Hess MA, Cabanillas F, Cox JD. Long-term results with radiotherapy for stage I-II follicular lymphomas. *International Journal of Radiation Oncology, Biology, Physics* 51(5):1219-27, 2001.
36. Michalski JM, Winter K, Purdy JA, **Wilder R**, Perez CA, Roach M, Parliament M, Pollack A, Markoe A, Harms WB, Sandler H, Cox JD. Trade-off to low-grade toxicity with conformal radiation therapy for prostate cancer on Radiation Therapy Oncology Group 9406. *Seminars in Radiation Oncology* 12(1 Suppl 1):75-80, 2002.
37. **Wilder RB**, Romaguera JE, Tucker SL, Ha CS, Hess MA, Cabanillas F, Cox JD. Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by radiotherapy with or without prechemotherapy surgical debulking for bulky, aggressive lymphoma. *Cancer* 94(3):601-5, 2002.
38. **Wilder RB**, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R. Persistence of myeloma protein for more than 1 year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. *Cancer* 94(5):1532-7, 2002.

39. **Wilder RB**, Schlembach PJ, Jones D, Chronowski GM, Ha CS, Younes A, Hagemeister FB, Barista I, Cabanillas F, Cox JD. European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. *Cancer* 94(6):1731-8, 2002.
40. Dabaja BS, Ha CS, Thomas DA, **Wilder RB**, Gopal R, Cortes J, Bueso-Ramos C, Hess MA, Cox JD, Kantarjian HM. The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. *Cancer* 94(10):2738-44, 2002.
41. **Wilder RB**, Rodriguez MA, Medeiros LJ, Tucker SL, Ha CS, Romaguera JE, Pro B, Hess MA, Cabanillas F, Cox JD. International prognostic index-based outcomes for diffuse large B-cell lymphomas. *Cancer* 94(12):3083-8, 2002.
42. Lee HK, \***Wilder RB**, Jones D, Ha CS, Pro B, Rodriguez MA, Romaguera JE, Cabanillas F, Rodriguez J, Cox JD. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. *Leukemia and Lymphoma* 43(9):1769-75, 2002.
43. Schlembach PJ, \***Wilder RB**, Jones D, Ha CS, Fayad LE, Younes A, Hagemeister F, Hess M, Cabanillas F, Cox JD. Radiotherapy alone for lymphocyte-predominant Hodgkin's disease. *The Cancer Journal* 8(5): 377-83, 2002.
44. Chronowski GM, \***Wilder RB**, Tucker SL, Ha CS, Sarris AH, Hagemeister FB, Barista I, Hess MA, Cabanillas F, Cox JD. An elevated serum beta-2 microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. *Cancer* 95(12):2534-8, 2002.
45. Chronowski GM, \***Wilder RB**, Tucker SL, Ha CS, Younes A, Fayad L, Rodriguez MA, Hagemeister FB, Barista I, Cabanillas F, Cox JD. Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy. *International Journal of Radiation Oncology, Biology, Physics* 55(1):36-43, 2003.
46. Kirsner SM, Kudchadker RJ, Prado KL, Ha CS, Lane RG, **Wilder RB**, Cox JD. Clinical implications of incorporating heterogeneity corrections in mantle field irradiation. *International Journal of Radiation Oncology, Biology, Physics* 55(4):1135-42, 2003.
47. Michalski JM, Winter K, Purdy JA, **Wilder RB**, Perez CA, Roach M, Parliament MB, Pollack A, Markoe AM, Harms W, Sandler HM, Cox JD. Preliminary evaluation of low-grade toxicity with conformal radiation

therapy for prostate cancer on RTOG 9406 dose levels I and II. *International Journal of Radiation Oncology, Biology, Physics* 56(1):192-8, 2003.

48. Dabaja BS, McLaughlin P, Ha CS, Pro B, Meyers CA, Seabrooke LF, **Wilder RB**, Kyritsis AP, Preti AH, Yung WK, Levin V, Cabanillas F, Cox JD. Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. *Cancer* 98(5):1021-8, 2003.

49. Ha CS, Kong JS, Tucker SL, McLaughlin P, **Wilder RB**, Hess MA, Cabanillas F, Cox JD. Central lymphatic irradiation for stage I-III follicular lymphoma: Report from a single-institutional prospective study. *International Journal of Radiation Oncology, Biology, Physics* 57(2):316-20, 2003.

50. Ha CS, Kong JS, McLaughlin P, Tucker SL, Fayad LE, Hess MA, **Wilder RB**, Cabanillas F, Cox JD. Stage III follicular lymphoma: Long-term follow-up and patterns of failure. *International Journal of Radiation Oncology, Biology, Physics* 57(3):748-54, 2003.

51. Dabaja BS, Ha CS, **Wilder RB**, Pro B, McLaughlin P, Cabanillas F, Cox JD. Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. *The Cancer Journal* 9(4):321-4, 2003.

52. Ha CS, Lee MS, McLaughlin P, Tucker SL, **Wilder RB**, Cox JD, Cabanillas F. Molecular response of follicular lymphoma to cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or COP-based therapy as measured by polymerase chain reaction evidence of translocation (14;18)(q32;q21). *The Cancer Journal* 10(1):49-53, 2004.

53. Chronowski GM, \***Wilder RB**, Levy LB, Atkinson EN, Ha CS, Hagemester FB, Barista I, Rodriguez MA, Sarris AH, Hess MA, Cabanillas F, Cox JD. Second malignancies after chemotherapy and radiotherapy for Hodgkin disease. *American Journal of Clinical Oncology* 27(1):73-80, 2004.

54. Lin P, Medeiros LJ, **Wilder RB**, Abruzzo LV, Manning JT, Jones D. The activation profile of tumour-associated reactive T-cells differs in the nodular and diffuse patterns of lymphocyte predominant Hodgkin's disease. *Histopathology* 44(6):561-9, 2004.

55. Brooks JP, Albert PS, **Wilder RB**, Gant DA, McLeod DG, Poggi MM. Long-term salvage radiotherapy outcome after radical prostatectomy and relapse predictors. *Journal of Urology*, 174(6):2204-8, 2005.

## B. Invited Articles

1. Cox JD, Ha CS, **Wilder RB**. Radiation therapy for malignant lymphoma: Enduring importance in the era of systemic therapy. *Biomedicine & Pharmacotherapy* 55(9-10):516-8, 2001.
2. Cox JD, Ha CS, Lee HK, Dabaja BS, **Wilder RB**. Uncertainties in contemporary treatment of aggressive lymphomas. *Rays* 28(3):289-92, 2003.

## C. Editorials

1. **Wilder RB**, DeNardo GL, DeNardo SJ. Treatment of cancer with intratumoral infusion of radioisotopes. *International Journal of Radiation Oncology, Biology, Physics* 30(3):737-9, 1994.
2. **Wilder RB**, Shen S, DeNardo GL. Dosimetry for radioimmunotherapy: A rapidly evolving field. *Cancer Biotherapy & Radiopharmaceuticals* 14(2):67-70, 1999.

## D. Book Chapters

1. **Wilder RB**, DeNardo SJ. Radioimmunotherapy. In: Leibel SA, Phillips TL (Eds), *Textbook of Radiation Oncology*, 1<sup>st</sup> edition. WB Saunders Company, Philadelphia, pp. 1293-1309, 1998.
2. **Wilder RB**, DeNardo SJ. Radioimmunotherapy of breast cancer. In: Riva P (Ed), *Cancer Radioimmunotherapy-Present and Future*, Harwood Academic Publishers, Amsterdam pp. 389-410, 1999.
3. Cox, JD, Ha CS, **Wilder RB**. Leukemias and lymphomas. In: Cox JD, Ang KK (Eds), *Radiation Oncology: Rationale, Technique, Results*, 8<sup>th</sup> edition. Mosby, St. Louis, pp. 821-55, 2003.
4. Ang KK, **Wilder RB**. The skin. In: Cox JD, Ang KK (Eds), *Radiation Oncology: Rationale, Technique, Results*, 8<sup>th</sup> edition. Mosby, St. Louis, pp. 127-43, 2003.
5. **Wilder RB**, Margolis LW. Cancer of the skin. In: Leibel SA, Phillips TL (Eds), *Textbook of Radiation Oncology*, 2<sup>nd</sup> edition. WB Saunders Company, Philadelphia, pp. 1483-1502, 2004.

## E. Manuals, Teaching Aids, Other Publications

For teaching purposes, I established a radiation oncology file at University of California, Davis and M. D. Anderson containing approximately 900 articles. I also made up a list of important articles on Hodgkin's disease, non-Hodgkin's lymphoma, and leukemia, and wrote a 62-page study guide for the written boards and 3- and 30-page study guides for the oral boards. In addition, I wrote an 84-page review of the literature on Hodgkin's

disease, non-Hodgkin's lymphoma, and leukemia. This teaching aid was given to National Capital Consortium/National Cancer Institute and M. D. Anderson residents.

## Editorial and Review Activities

### Journal Reviewer

International Journal of Cancer, 1994

Cancer Research, 1995

Pharmaceutical Science & Technology Today, 1998

Journal of Brachytherapy International, 1998

European Journal of Cancer, 2001

International Journal of Radiation Oncology, Biology, Physics, 1999-present

## Teaching

### Residents and Fellows

I have previously had the pleasure of working with the following 60 University of California, San Francisco, M. D. Anderson, and National Capital Consortium/National Cancer Institute residents and fellows:

Michael Weil	Mark Storey	Wendy Woodward
Stella Ling	Pamela Schlembach	Yerko Borghero
Aidnag Diaz	Greg Chronowski	Anurag Chandra
Marion Scholz	Becki Hill	Steven Frank
Richard Crownover	Angela Katz	Annie Ahamad
Loan Tran	Noah Taylor	Catherine Lee
Maria-Amelia Gonzales	Arthur Hung	Kevin Sanders
Anita Chen	Harold Freeman	Bouthaina Dabaja
Rachel Chou	Matthew Callister	Alan Gant
Lori Coleman	Arthur Chaney	Matt Poggi
David Koeplin	Robert Liebross	Dustin Boyer
Julie Minkow Forstner	Ramesh Gopal	Deborah Citrin
Hui-Kuo Shu	Hoon Lee	Joseph Brooks
Quynh-Thu Le	Michael Hanus	Eric Friedman
Lloyd Miyawaki	Isadora Arzu	Michael Brown
Cardella Coleman	Laura Freedman	Atmaram Pai Panandiker
Joseph Song	Jennifer De Los Santos	John Mansueti
Steven Seung	Tse-Kuan Yu	Nikki Simone

Marc Posner  
Samantha Seaward

Mark Bonnen  
Darren Little

Bronwyn Stall  
Deedee Smart

### Organization of National or International Conferences/Symposia (Include chairing session)

On April 24, 2001, I chaired the “Advances in the treatment of cancer of the lung and esophagus” session entitled “New Concepts in the Biology and Treatment of Cancer” at the Japan/U.S. Cancer Therapy Symposium (JUCTS) in La Jolla, CA.

## Presentations at National or International Conferences

### Invited Panel Presentations

1. Is radiation therapy alone sufficient for selected cases of early-stage classical Hodgkin’s disease?, Lymphoma...The Next Questions Conference, Washington, D.C., 10/12/01.
2. Ha CS, **Wilder RB**, Cox JD. RSNA Refresher Course #119.B: Lymphoma. Presented by Drs. Ha & Cox on November 25, 2001, at the 87<sup>th</sup> Scientific Assembly and Annual Meeting of the Radiological Society of North America, Chicago, IL.
3. Dose-response analysis for aggressive lymphomas, RadOnc 2002, M. D. Anderson, Houston, TX, 2/21/02. Can we use radiation therapy to treat patients with large cell NHL whose maximum response is a PR?, Lymphoma...The Next Questions Conference, San Juan, Puerto Rico, 4/25/03

### Invited Poster Presentations over the Past Year

1. Tokita KM, Futami L, Khanijou R, Curcio L, Kakkis J, Ravera J, **Wilder RB**. Preliminary Results in 180 Patients Treated with Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer. Presented at the 90<sup>th</sup> Annual Meeting of the American Radium Society, May 3-7, 2008, Dana Point, CA.
2. Chittenden L, Mesa A, Bunyapanasarn J, Agustin J, Ravera J, Tokita K, **Wilder RB**. An Analysis of Intrafraction Prostate Motion in the Prone vs. Supine Treatment Positions for Intensity-Modulated Radiation Therapy. Presented at the 50<sup>th</sup> Annual Meeting of the American Society for Therapeutic Radiology and Oncology, September 21-25, 2008, Boston, MA.
3. Tokita KM, Chittenden L, Futami L, Khanijou R, Curcio L, Kakkis J, Ravera J, **Wilder RB**. Preliminary Results in 175 Patients Treated with Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer. Presented at the 50<sup>th</sup> Annual Meeting of the American Society for Therapeutic Radiology and Oncology, September 21-25, 2008, Boston, MA.

4. **Wilder RB**, Mesa AV, Chittenden L, Curcio LD, Khanijou RK, Kakkis J, Eisner ME, Ravera J, Tokita KM. A Contura™ Catheter Provides Dosimetric Advantages Over a MammoSite Catheter for Accelerated Partial Breast Irradiation. Presented at the 31<sup>st</sup> Annual San Antonio Breast Cancer Symposium, December 10-14, 2008, San Antonio, TX.

#### Other, Including Scientific Exhibitions

Faculty, University of California, Davis and University of California, San Francisco, 1993-1999

Faculty, University of Texas M. D. Anderson Cancer Center, 1999-2002

#### Courses:

Instructor, Allied Health Education in Radiation Oncology Program, M. D. Anderson, 2000-2002. The one-hour lectures on Hodgkin's disease and non-Hodgkin's lymphoma were televised to radiation therapy and dosimetry students at the UT Southwestern Moncrief Cancer Center in Fort Worth, TX, UT Medical Branch in Galveston, TX, and Scott & White Memorial Hospital in Austin, TX.

1. Instructor, Methods of improving the efficacy of radioimmunotherapy, Radiation Oncology Lecture Series, Stanford University Medical Center, Stanford, CA, 9/25/92.

2. Instructor, Treatment of arteriovenous malformations with stereotactic radiosurgery, Sixteenth Annual Surgical Postgraduate Course, U. C. Davis Medical Center, Sacramento, CA, 1/15/94.

3. Instructor, The role of radiation therapy in the treatment of localized prostate cancer, Prostate Cancer: An Interactive Workshop, Sierra Nevada Memorial Hospital, Grass Valley, CA, 6/13/98.

4. Instructor, Treatment of tumors with stereotactic radiosurgery, Radiation Oncology Lecture Series, M. D. Anderson, Houston, TX, 9/28/99.

5. Instructor, Diffuse lymphomas, Radiation Oncology Lecture Series, M. D. Anderson, Houston, TX, 3/7/00.

6. Instructor, Follicular lymphomas, Radiation Oncology Lecture Series, M. D. Anderson, Houston, TX, 3/9/00.

7. Instructor, Hodgkin's disease and non-Hodgkin's lymphoma case presentations, Radiation Oncology Internal Visiting Professor Program, M. D. Anderson, Houston, TX, 11/9/00.

8. Instructor, Non-Hodgkin's lymphomas, Radiation Oncology Lecture Series, M. D. Anderson, Houston, TX, 4/10/01.
9. Instructor, Is there still a role for radiotherapy alone for nonbulky, stage IA-IIA Hodgkin's disease? Radiation Oncology Lecture Series, M. D. Anderson, Houston, TX, 9/18/01.
10. Instructor, Treatment of arteriovenous malformations with stereotactic radiosurgery, Radiation Oncology Lecture Series, M. D. Anderson, Houston, TX, 3/22/02.
11. Instructor, Is there still a role for radiotherapy alone for nonbulky, stage IA-IIA Hodgkin's disease? Radiation Oncology Lecture Series, Howard University Hospital, Washington, DC, 12/16/03.

#### Seminar Invitations from Other Institutions

1. Stereotactic radiosurgery, Surgery Grand Rounds, U. C. Davis Medical Center, Sacramento, CA, 1/27/94.
2. Stereotactic radiosurgery, Surgery Grand Rounds, San Joaquin General Hospital, Stockton, CA, 4/6/94.
3. Stereotactic radiosurgery, Woodland Healthcare Clinical Conference, Woodland, CA, 7/27/94.
4. Treatment of carcinoma of the skin with radiation therapy, ENT Grand Rounds, U. C. Davis Medical Center, Sacramento, CA, 11/11/94.
5. Stereotactic radiosurgery, Neurosurgery Grand Rounds, U. C. Davis Medical Center, Sacramento, CA, 3/15/95.
6. Stereotactic radiosurgery, Neuroradiology Grand Rounds, Sutter General Hospital, Sacramento, CA, 3/28/95.
7. Treatment of carcinoma of the skin with radiation therapy, Surgery Grand Rounds, San Joaquin General Hospital, Stockton, CA, 5/3/95.
8. Treatment of tumors with stereotactic radiosurgery, Neurosurgery Grand Rounds, U. C. Davis Medical Center, Sacramento, CA, 5/15/96.
9. Phase III RTOG protocols for head and neck cancer, ENT Grand Rounds, U. C. Davis Medical Center, Sacramento, CA, 6/21/96.

10. Treatment of carcinoma of the skin with radiation therapy, Dermatologic Surgery Didactic Core Curriculum, U. C. Davis Medical Center, Sacramento, CA, 6/26/96.
11. Treatment of brain tumors with stereotactic radiosurgery, Section of Radiodiagnosis and Therapy Seminar, U. C. Davis Medical Center, Sacramento, CA, 10/10/96.
12. Treatment of tumors with stereotactic radiosurgery, ENT Grand Rounds, U. C. Davis Medical Center, Sacramento, CA, 2/14/97.
13. The use of radiation therapy in the treatment of prostate & bladder cancer, 13th Annual Cancer Symposium, Memorial Regional Cancer Center, Modesto, CA, 9/20/97.
14. The role of radiation therapy in the treatment of prostate cancer, Urology Grand Rounds, U. C. Davis Medical Center, Sacramento, CA, 9/30/97.
15. Treatment of cutaneous carcinomas and keloids with radiotherapy, Dermatology Grand Rounds, U. C. Davis Medical Center, Sacramento, CA, 7/22/98.
16. Dose-response analysis for aggressive lymphomas, Division of Radiation Oncology Grand Rounds, M. D. Anderson, Houston, TX, 10/3/01.
17. The current role of radiotherapy in patients with early-stage Hodgkin's disease, Cancer Foundation of Santa Barbara, Santa Barbara, CA, 1/11/02.

#### Other Presentations (state, local) Conferences

1. Current management of prostate cancer, Patient Support Group, U. C. Davis Medical Center, Sacramento, CA, 9/13/93.
2. Stereotactic radiosurgery, Northern California Society of Radiation Therapists' Symposium, U. C. Davis Medical Center, Sacramento, CA, 8/27/94.
3. Treatment of arteriovenous malformations with stereotactic radiosurgery, Tumor Registrars' Association of California Meeting, U. C. Davis Medical Center, Sacramento, CA, 7/14/95.
4. Treatment of tumors with stereotactic radiosurgery, River Cities Chapter of the American Association for Medical Transcription, Sacramento, CA, 9/26/98.

5. Brain tumor research protocols, Brain Tumor Support Group, U. C. Davis Medical Center, Sacramento, CA, 3/4/99.

6. Stereotactic radiosurgery, Partners In Knowledge, News In Cancer, M. D. Anderson, Houston, TX, 6/29/99.

7. Advances in radiotherapeutic technique for Hodgkin's disease, Lymphoma Research Conference, M. D. Anderson, Houston, TX, 10/17/01.

## Professional Memberships / Activities

### Professional Society Activities, with Offices Held

#### Local / state

Member, California Radiological Society, 1993-1999

Member, Northern California Radiation Oncology Society, 1994-1999

Member, Gilbert H. Fletcher Society, 2000-2002

#### National and International

Member, Southwest Oncology Group, 1994-1999

Member, American College of Radiation Oncology, 1992-2002

Member, American College of Radiology, 1993-2002

Member, Radiation Therapy Oncology Group, 1994-2002

Member, American Society of Clinical Oncology, 1998-2002

Member, American Society for Therapeutic Radiology and Oncology, 1989-present

## OTHER

Abstract reviewer (1 of 7 lymphoma reviewers) for Annual Meetings of the American Society of Therapeutic Radiology and Oncology, 2002-2007